Results of a phase III clinical trial presented at the 36th San Antonio Breast Cancer Symposium (SABCS), being held December 10?14, 2013 in San Antonio, Texas, shows that women with metastatic breast cancer who have elevated amounts of circulating tumor cells or CTCs in their blood after a first line of chemotherapy do not benefit from switching immediately to a different chemotherapy. The trial does not show an improvement in overall survival or time to progression.[1][2]
Rapid creation of abnormal cells called circulating tumor cells, that grow beyond their usual boundaries or escape via the lymphatic system or blood circulatory system, invade adjoining parts of the body and spread to other organs, a process called metastasizing, is causeing the majority of cancer deaths. CTCs have become an important object for cancer research.
Not a good marker
?We concluded that CTCs are not a good marker in helping to decide when to switch between chemotherapies,? explained Jeffrey B. Smerage, M.D., Ph.D., clinical associate professor at the University of Michigan Comprehensive Cancer Center in Ann Arbor. ?It had been hoped that switching would both increase the chances of being on an effective therapy and decrease the exposure to toxicity from less effective or ineffective therapies, and as a result it had been hoped that this early switching would result in improved survival and time to progression.”
This… patient population needs more effective treatment options beyond traditional chemotherapy…
Implication for the clinic
?The most important implication is that we have validated that the group of patients with elevated CTCs at both baseline and 21 days after starting their first chemotherapy has a worse prognosis with regard to both time to progression and overall survival,? Smerage added. ?Although chemotherapy may work for these patients, it clearly does not work as long as one would like. This suggests that this patient population needs more effective treatment options beyond traditional chemotherapy. Given that these patients have higher cancer-related risks, early consideration of clinical trial participation would be appropriate.?
About 75% of patients with metastatic breast cancer have CTCs detectable in their blood, and the number of CTCs is elevated in about half of these patients (?5CTC/7.5 ml whole blood (WB)). The presence of elevated CTCs in blood indicates poor prognosis and relatively short time to progression, and the goal of this trial was to evaluate if switching to a different chemotherapy is beneficial for patients whose elevated CTCs did not drop after initial chemotherapy.
SWOG S0500 trial
However, the trial results showed that changing therapy for patients with elevated CTCs after one cycle of initial chemotherapy did not improve their overall survival, the primary endpoint of this study.
?An important secondary endpoint was to evaluate whether the levels of CTCs before and after starting a chemotherapy provided prognostic information on how long a patient might live,? Smerage noted. ?This study confirmed that patients who have low numbers of CTCs before
starting chemotherapy have a much better survival. They had a median overall survival of 35 months, which means that half of these patients lived three years or longer, and some substantially longer.”
?On the other hand, patients for whom CTCs remained elevated after one cycle of chemotherapy had substantially worse survival. They had a median overall survival of only 13 months,? he explained. ?This suggests that chemotherapy may not be as effective for these cancers in which CTCs remain elevated after one cycle of chemotherapy. This doesn?t mean that chemotherapy has no benefit, but it suggests that the benefit is limited.?
Trial results
Smerage and colleagues conducted a prospective, randomized, phase III trial, called the SWOG S0500 trial, to which they recruited 624 patients between 2006 and 2012. All participants had either measurable disease or evaluable disease that included bone metastases. Of the 595 patients who were eligible for the trial, 276 had low CTCs at baseline, and were observed on Arm A. These patients continued to receive the initial chemotherapy. The remaining 319 patients had elevated CTCs at baseline, and 286 had a CTC result available at
day 21 of the first cycle of chemotherapy. At day 21, CTCs decreased to lower levels in 163 patients, who were observed on Arm B. These patients continued to receive the initial chemotherapy.
The 123 patients who continued to have elevated CTCs at day 21 were either randomly assigned to arm C1 and continued to receive the initial chemotherapy (64 patients) or were randomly assigned to arm C2 and had their treatment changed to a second-line chemotherapy (59 patients). ?This study was based on counting the number of CTCs in blood,? explained Smerage. ?Several groups are now investigating the presence of biological markers such as estrogen receptor,
HER2, and others on CTCs. It is hoped that the measurement of these markers may allow for better prediction of what therapies will work best for these patients.?
This study was funded by the National Cancer Institute, and in part by Veridex. Jeffrey B.Smerage declares no conflicts of interest.
For more information:
[1] Smerage JB, Barlow WE, Hayes DF, Winer EP, Leyland-Jones B, Srkalovic G, Tejwani S, et al. SWOG S0500 ? A randomized phase III trial to test the strategy of changing therapy versus maintaining therapy for metastatic breast cancer patients who have elevated circulating tumor cell (CTC) levels at first follow-up assessment. Publication Number: S5-07. Presented by Jeffrey B. Smerage, M.D., Ph.D.
[2]NCT00382018 – S0500 Treatment Decision Making Based on Blood Levels of Tumor Cells in Women With Metastatic Breast Cancer Receiving Chemotherapy [Study Record Detail]
Copyright ? 2013 InPress Media Group/Sunvalley Communication. All rights reserved. Republication or redistribution of InPress Media Group/Sunvalley Communication content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group/Sunvalley Communication. InPress Media Group/Sunvalley Communication shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Onco’Zine and Oncozine are registered trademarks and trademarks of Sunvalley Communication around the world.
